3 completed, 3 unknown, 2 recruiting, 1 active not recruiting. 6 Phase 2, 1 Not applicable, 1 Phase 3, 1 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 6 | Unknown 3, Active not recruiting 1, Recruiting 1, Terminated 1 |
| Not applicable | 1 | Completed 1 |
| Phase 3 | 1 | Recruiting 1 |
| Phase 4 | 1 | Completed 1 |
Follow Mercator MedSystems, Inc.: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Temsirolimus Adventitial Delivery to Improve ANGioplasty and/or Atherectomy Revascularization Outcomes Below the Knee Temsirolimus, Saline placebo - Peripheral Artery Disease, Critical Limb Ischemia | Phase 3 | Recruiting | Mercator MedSystems, Inc. | 250 | 2025-07-30 | 2025-08-05 |
| Perivenous Dexamethasone Therapy: Examining Reduction of Inflammation After Thrombus Removal to Yield Benefit in Subacute and Chronic Iliofemoral DVT Perivascular dexamethasone, Perivascular sham - Iliofemoral; Thrombosis | Phase 2 | Active not recruiting | Mercator MedSystems, Inc. | 60 | 2022-08-08 | 2026-06-25 |
| Perivenous Dexamethasone Therapy: Examining Reduction of Inflammation After Thrombus Removal to Yield Benefit in Acute Femoropopliteal DVT Perivascular dexamethasone, Perivascular sham - Thrombosis, Deep Vein, Iliofemoral; Thrombosis | Phase 2 | Recruiting | Mercator MedSystems, Inc. | 80 | 2021-10-29 | 2026-09-25 |
| Temsirolimus Alone or Paired With Dexamethasone Delivered to the Adventitia to eNhance Clinical Efficacy After Femoropopliteal Revascularization Temsirolimus, Temsirolimus and dexamethasone sodium phosphate - Peripheral Arterial Disease | Phase 2 | Terminated | Mercator MedSystems, Inc. | 10 | 2019-10-01 | 2024-07-10 |
| Temsirolimus Adventitial Delivery to Improve Angiographic Outcomes Below the Knee (TANGO) Temsirolimus, Saline - Chronic Limb Ischemia | Phase 2 | Unknown | Mercator MedSystems, Inc. | 100 | 2017-03-03 | 2020-06-11 |
| Lower-Limb Adventitial Infusion of DexaMethasone Via Bullfrog to Reduce Occurrence of Restenosis After Atherectomy (ATX)-Based Revascularization Dexamethasone Sodium Phosphate Injection, USP, 4 mg/mL - Chronic Limb Ischemia | Phase 2 | Unknown | Mercator MedSystems, Inc. | 120 | 2016-06-01 | 2020-02-19 |
| Lower-Limb Adventitial Infusion of DexaMethasone Via Bullfrog to Reduce Occurrence of Restenosis After Percutaneous Transluminal Angioplasty Revascularization Dexamethasone sodium phosphate injection, USP, 4 mg/mL - Chronic Limb Ischemia | Phase 2 | Unknown | Mercator MedSystems, Inc. | 120 | 2016-01-01 | 2020-02-20 |
| DANCE Partner: Inflammatory Biomarker Analysis by Femoropopliteal Revascularization Method and Treatment Outcomes Balloon Angioplasty, Atherectomy System - Peripheral Arterial Disease | Completed | Mercator MedSystems, Inc. | 31 | 2015-05-01 | 2018-03-08 | |
| Broncho-Adventitial Delivery of Paclitaxel to Extend Airway Patency in Malignant Airway Obstruction Patients Paclitaxel - Malignant Airway Obstruction Secondary to Non-small Cell Lung Cancer | Not applicable | Completed | Mercator MedSystems, Inc. | 20 | 2014-07-01 | 2018-04-20 |
| Effectiveness of Adventitial Dexamethasone in Peripheral Artery Disease Dexamethasone Sodium Phosphate Injection, USP - Peripheral Arterial Diseases | Phase 4 | Completed | Mercator MedSystems, Inc. | 285 | 2013-11-01 | 2018-03-08 |
Peripheral Arterial Disease (4) · Thrombosis (2) · Chronic Limb-Threatening Ischemia (1) · Inflammation (1) · Venous Thrombosis (1)
dexamethasone 21-phosphate (4) · temsirolimus (3) · Angioplasty, Balloon (1) · Paclitaxel (1) · Sodium Chloride (1)
United States (9) · Ireland (2) · United Kingdom (2) · Germany (1)
Dierk Scheinert, MD (1) · Donald Jacobs, MD (1) · George Adams, MD (1) · Jason A Yoho, MD (1) · Mahmood Razavi, MD (1)
R42CA141907 (1), R44HL160434 (1)